Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection

Chuan-Yong Guo, Yun-Bin Wu, Heng-Lu Liu, Jian-Ye Wu, Min-Zhang Zhong

AIM: To evaluate clinical efficacy of four one-week triple therapies in eradicating Helicobacter pylori infection.

METHODS: In this clinical trial, 132 patients with duodenal ulcer and chronic gastritis were randomly divided into four groups, and received treatment with OAC (omeprazole 20 mg + amoxicillin 1 000 mg + clarithromycin 250 mg), OFC (omeprazole 20 mg + furazolidone 100 mg + clarithromycin 250 mg), OFA (omeprazole 20 mg + furazolidone 100 mg + amoxicillin 1 000 mg) and OMC (omeprazole 20 mg + metronidazole 200 mg + clarithromycin 250 mg), respectively. Each drug was taken twice daily for one week. The 13C urea breath test was carried out 4-8 weeks after treatment to determine the success of H pylori eradication.

RESULTS: A total of 127 patients completed the treatment. The eradication rate for H pylori infection was 90.3%, 90.9%, 70.9% and 65.6%, respectively in OAC, OFC OMC and OFA groups.

CONCLUSION: A high eradication rate can be achieved with one-week OAC or OFC triple therapy. Thus, one-week triple therapies with OAC and OFC are recommended for Chinese patients with duodenal ulcers and chronic gastritis.

Guo CY, Wu YB, Liu HL, Wu JY, Zhong MZ. Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection. World J Gastroenterol 2004; 10(5): 747-749 http://www.wjgnet.com/1007-9327/10/747.asp

INTRODUCTION

Eradication of Helicobacter pylori infection has become a wide clinical practice for H pylori related diseases such as peptic ulcers, and considerable clinical efficacy has been achieved over the past two decades[1-6]. However, many short-term (one week) triple therapy regimens include metronidazole and suffer from the problem of metronidazole resistance, which could significantly decreases clinical efficacy[7-11]. Therefore, it is a very important issue to search for anti-H pylori regimens that are highly effective in eradicating H pylori infection but without drug resistance[12]. The aim of the present study was to evaluate the clinical efficacy of four short-term triple therapy regimens with clarithromycin.

MATERIALS AND METHODS

Selection of patients

Parameters of selection (1) Those aged 18-70 years. (2) Those with duodenal ulcer (DU) or chronic gastritis (CG) confirmed by gastroscopy. (3) Those who were positive for H pylori by a rapid urease test (RUT) and positive by serology, silver or Giemsa staining and histological examination.

Criteria of exclusion (1) Patients who had gastric ulcer or severe gastroesophageal reflux disease, and those who had gastric operation history, hemolytic anemia or family history of hemolytic anemia. (2) Patients who were in lactation or pregnancy. (3) Patients who had combined severe diseases of other system that might affect the medical evaluation of this study. (4) Patients who took the drugs included in this study over the past month. (5) Patients who was allergic to the drugs included in this study.

Methods

Drugs Omeprazole (20 mg/cap, Changzhou fourth Pharmaceutical Factory), clarithromycin (250 mg/tab, Hangzhou Chinese-American Eastchina Pharmaceutical Co. Ltd), furazolidone (100 mg/tab, Guangdong Jiangmen Pharmaceutical Factory), metronidazole (200 mg/tab, Shanghai Ensay Pharmaceutical Co. Ltd) and amoxicillin (250 mg/cap, Kunming Baker Norton Pharmaceutical Co. Ltd) were used.

Regimens Patients were randomly divided into four groups, and receive treatment with OAC (omeprazole 20 mg + amoxicillin 1 000 mg + clarithromycin 250 mg), OFC (omeprazole 20 mg + furazolidone 100 mg + clarithromycin 250 mg), OMC (omeprazole 20 mg + metronidazole 200 mg + clarithromycin 250 mg) and OFA (omeprazole 20 mg + furazolidone 100 mg + amoxicillin 1 000 mg), respectively. Each group took the drugs twice a day for 7 d.

Procedures At the entry, clinical symptoms, demographic data and medical history were recorded, and gastroscopy was performed to establish the endoscopic diagnosis and status of H pylori infection. During the gastroscopy examination, four biopsy specimens were taken from stomach: one for a rapid urease test (RUT), one for silver or modified Giemsa staining, and two for histological examination. Serum anti-H pylori IgG antibodies were also detected. The patients who were intensive positive by the RUT (positive in five minutes) were initially considered to be qualified for the study. Only those patients who were also positive by serology, H pylori staining and histological examination were included in the clinical trial. Patients were followed up on the eighth day to check clinical symptoms, side effects and compliance. A 13C urea breath test was carried out 4-8 wk after completion of the therapy.

Definition of H pylori eradication H pylori eradication was defined when the 13C urea breath test was negative 4-8 weeks after completion of anti-H pylori therapy.

Statistical analysis

H pylori eradication rate was the main analytic target. Total eradication rate and its 95% confidence interval of each regimen was calculated and analyzed by intention-to-treat.
analysis (ITT) and per protocol (PP), respectively. The significance in the difference of eradication rate between various regimens was tested by Fisher exact probability and Chi-square test. The possible factors affecting eradication rate was analyzed in a logistic regression model. The difference in the incidence of side effects of each regimen was tested by Fisher exact probability test.

**RESULTS**

**Demographic and clinical data**

Of the 132 patients enrolled in the study, 127 (96.2%) completed the treatment and five (3.8%) dropped off. The demographic data and the proportion of DU and CG were not significantly different among the groups (Table 1).

**Table 1** Comparison between patient age gender and endoscopic diagnostic results of each group

| Group | n  | Male/Female | Age (years) | DU/ CG |
|-------|----|-------------|-------------|--------|
| OAC   | 33 | 20/ 13      | 43.5(18-70) | 18/ 15 |
| OFC   | 33 | 19/ 14      | 40.8(20-70) | 17/ 16 |
| OMC   | 33 | 21/ 12      | 41.6(19-69) | 18/ 15 |
| OFA   | 33 | 20/ 13      | 41.2(20-70) | 19/ 14 |
| Total | 132| 80/ 52      | 42.0(18-70) | 72/ 64 |

**H pylori eradication rates**

*H pylori* eradication rates were significantly different in patients receiving OAC and OFC than in those receiving OMC and OFA (*P*<0.05) (Tables 2 and 3). In the logistic regression model including treatment regimen, age, sex and endoscopes diagnosis, treatment regimens were identified as an independent factor responsible for the difference in the eradication rate (Table 3).

**Table 2** *H pylori* eradication rate in each group

| Group | n  | Eradication rate (%) | Confidence interval (95%) | n  | Eradication rate (%) | Confidence interval (95%) |
|-------|----|----------------------|---------------------------|----|----------------------|---------------------------|
| OAC   | 31 | 90.3                 | 79.9-95.6                 | 33 | 84.9                 | 80.1-92.3                 |
| OFC   | 33 | 90.9                 | 78.5-97.3                 | 33 | 90.9                 | 79.6-95.4                 |
| OMC   | 31 | 70.9                 | 64.0-81.7                 | 33 | 66.7                 | 62.5-76.7                 |
| OFA   | 32 | 65.6                 | 59.9-72.2                 | 33 | 63.6                 | 60.2-71.6                 |
| Total | 127| 79.5                 | 72.4-82.5                 | 33 | 76.5                 | 70.5-81.8                 |

**Table 3** *H pylori* eradication rate in each group in relation to endoscopic diagnosis

| Group | n  | Duodenal ulcer Eradication rate (%) | Chronic gastritis Eradication rate (%) |
|-------|----|-------------------------------------|---------------------------------------|
| OAC   | 17 | 88.2                                | 14                                    |
| OFC   | 17 | 94.1                                | 16                                    |
| OMC   | 16 | 68.8                                | 15                                    |
| OFA   | 19 | 57.9                                | 13                                    |
| Total | 69 | 76.8                                | 58                                    |

**Incidence of side effects**

The incidence of side effects varied among the treatment regimens (Table 4). All of side effects were slight. A compliance of >90% was achieved for all the patients who completed the study.

**Table 4** Incidence of side effects in each group

| Side effects                                      | OAC (n=31) | OFC (n=33) | OMC (n=31) | OFA (n=32) | Total (n=127) |
|---------------------------------------------------|------------|------------|------------|------------|---------------|
| Gastroenteric reactions                           | 6.45       | 9.09       | 12.9       | 9.38       | 9.45          |
| Skin eruption                                     | 6.45       | 0          | 3.23       | 6.25       | 3.94          |
| Headache                                          | 6.45       | 6.06       | 3.23       | 0          | 4.72          |
| Glossitis                                         | 0          | 0          | 3.23       | 0          | 0.79          |
| Weakness                                          | 0          | 0          | 3.23       | 0          | 0.79          |
| Fever                                             | 0          | 3.03       | 0          | 0          | 0.79          |
| Somnolence                                        | 3.23       | 0          | 3.23       | 0          | 1.57          |

**DISCUSSION**

In 1990, the 14-d bismuth triple therapy was recommended in the Ninth World Gastroenterology Conference in Sydney. Due to its high incidence of side effects (higher than 30%) and poor compliance, this regimen has been replaced with other short-term 7-day triple therapy regimens that are more efficient and had fewer and milder side effects[13-19]. These new regimens include OMC 250 and OAC 500, which achieved *H pylori* eradication rates of more than 90% in the MACH-1 study[20-26]. However, the eradication rates with these regimens decreased due to emergence of metronidazole resistance in *H pylori* over the past few years. It has been reported that prevalence of metronidazole resistant *H pylori* strains has increased to more than 70% in China and other countries[27-31]. This accounts for the failure of *H pylori* eradication with metronidazole triple therapy.

With the wide application of anti-*H pylori* therapy and antibiotic abuse, drug resistance in *H pylori* has become an increasingly serious problem and a major reason of poor curative effect. At present[30,31], the resistance to clarithromycin in *H pylori* is diverse in the world. South-north difference existed such as the drugs used to treat other infection before (mainly respiratory infection). There are significant differences in the prevalence of metronidazole resistance between developed and developing countries. High prevalence of metronidazole resistance mainly relates to the wide application in parasite infection, dental infection and gynecological diseases in developing countries. Now there is a tendency that metronidazole resistance in *H pylori* is increasing in the developed countries, probably due to the application of anti-*H pylori* therapy. In spite of widespread treatment with amoxicillin, amoxicillin resistance in *H pylori* was rare.

In order to overcome the problem of metronidazole resistance and to compare the clinical efficacy of triple therapy regimens containing clarithromycin, we carried out this study. We achieved relatively high eradication rates for the clarithromycin-containing regimens OAC and OFC (90.3% and 90.9%, respectively). On the other hand, the eradication rate was relatively low for the metronidazole-containing regimen OMC and OFA. Taken together, we conclude that OAC and OFC are efficient regimens in eradicating *H pylori* infection. Since the cost of furazolidone in OFC regimen is cheap and the *H pylori* eradication rate of OFC regimen is high, we recommend that this regimen be one of choices for *H pylori* eradication.

**REFERENCES**

1. **Marzio L**, Cellini L, Angelucci D. Triple therapy for 7 days vs triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with *H. pylori* infection. A double blind placebo controlled trial. *Dig Liver Dis* 2003; 35: 20-23
2 Sargyn M, Uygur-Bayramici O, Sargyn H, Orbay E, Yavuzer D, Yayaia A. Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori. World J Gastroenterol 2003; 9: 1126-1128

3 Yamada T, Miwa H, Fujino T, Hira S, Yokoyama T, Sato N. Improvement of Gastric Atrophy After Helicobacter pylori Eradication Therapy. J Clin Gastroenterol 2003; 36: 405-410

4 Li S, Lu AP, Zhang L, Li YD. Anti-Helicobacter pylori immunglobulin G (IgG) and IgA antibody responses and the value of clinical presentations in diagnosis of H pylori infection in patients with precancerous lesions. World J Gastroenterol 2003; 9: 755-758

5 Konturej SK, Brzozowski T, Konturek PC, Kwiecien S, Karczewska E, Drozdowicz D, Scharuher J, Hahn EG. Helicobacter pylori infection delays healing of ischemia-reperfusion induced gastric ulcerations: a new animal model for studying pathogenesis and therapy of H pylori infection. Eur J Gastroenterol Hepatol 2002; 12: 1299-1313

6 Goh KL. Update on the management of Helicobacter pylori infection, including drug-resistant organisms. J Gastroenterol Hepatol 2002; 17: 482-487

7 Wolle K, Leedolter A, Malfertheiner P, Konig W. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002; 51: 705-709

8 Bruley Des Varannes S. How to treat after Helicobacter pylori eradication failure? Gastroenterol Clin Biol 2003; 27: 478-483

9 Hua JS, Bow H, Zhang PY, Khay-Guan Y. Prevalence of primary resistance to metronidazole and clarithromycin resistance in metronidazole-susceptible and -resistant isolates of Helicobacter pylori cultured from treated mice. Antimicrob Agents Chemother 2003; 49: 675-678

10 Ivashkin VT, Lapina TL, Bondarenko OY, Sklanskaya OA, Grigoriev PY, Vasiliev YY, Gulyaev PV, Fedchenko VI. Azithromycin in a triple therapy for H pylori eradication in active duodenal ulcer. World J Gastroenterol 2002; 8: 879-882

11 Lam RK, Labigne A, Jenks PJ. Production of the RdxA protein in metronidazole -susceptible and -resistant isolates of Helicobacter pylori cultured from treated mice. J Antimicrob Chemother 2003; 50: 679-683

12 Marais A, Bilardi C, Cantet F, Mendoza GL, Megraud F. Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori. Res Microbiol 2003; 154: 137-144

13 O’Morain C, Borody T, Farley A, De Boer WA, Dallaire C, Schuman R, Piotrowski J, Fallone CA, Tytgat G, Megraud F, Spenard J. International multicentre study. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and clarithromycin in the treatment of Helicobacter pylori infection: the BAC-MACH Study. Aliment Pharmacol Ther 1999: 13: 1079-1084

14 Malfertheiner P, Bayerdorffer E, Dietze U, Gil J, Lind T, Misiuna P, O’Morain C, Sipponen P, Spiller RC, Stasiwicz J, Treichel H, Ujjasztesy L, Unge P, Zanten SJ, Zeijlon L. The QU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999: 13: 703-712

15 Unge P. The OAC and OMC options. Eur J Gastroenterol Hepatol 1999: 11: 23-24

16 Spiller RC. Is there any difference in Helicobacter pylori eradication rates in patients with active peptic ulcer, inactive peptic ulcer and functional dyspepsia? Eur J Gastroenterol Hepatol 1999: 11: 43-45

17 Megraud F, Lehn N, Lind T, Bayerdorffer E, O’Morain C, Spiller R, Unge P, van Zanten SV, Wramstad M, Burman CF. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999: 43: 2747-2752

18 Jenks PJ, Edwards DI. Metronidazole resistance in Helicobacter pylori. Int J Antimicrob Agents 2002; 19: 1-7

19 Calvet X, Ducons J, Guardiola J, Tito L, Andreu V, Bory F, Guirao R. One-week triple vs quadruple therapy for Helicobacter pylori infection: a randomized trial. Aliment Pharmacol Ther 2002; 16: 1261-1267

20 Owen RJ, Ferrus M, Gibson J. Amplified fragment length polymorphism genotyping of metronidazole-resistant Helicobacter pylori infecting dyspeptics in England. Clin Microbiol Infect 2001; 7: 244-253

21 Yokoo J, Fan X, Hu G, Liu L, Zhang Z. Antibiotic susceptibility of Helicobacter pylori in the Chinese population. J Gastroenterol Hepatol 2001; 16: 961-965

22 Isakov V, Domareva I, Koudryavtseva L, Maev I, Ganskaya Z. Furazolidone-based triple ‘rescue therapy’ vs quadruple ‘rescue therapy’ for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther 2002; 16: 1277-1282

Edited by Wang XL